

Devjit Tripathy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8520386/publications.pdf>

Version: 2024-02-01

60
papers

8,280
citations

109321

35
h-index

138484

58
g-index

60
all docs

60
docs citations

60
times ranked

11918
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to Letter to the Editor from Roy et al: "Impaired Suppression of Glucagon in Obese Subjects Parallels Decline in Insulin Sensitivity and Beta-Cell Function" Journal of Clinical Endocrinology and Metabolism, 2022, 107, e1331-e1332.	3.6	0
2	Effects of Sustained Hyperglycemia on Skeletal Muscle Lipids in Healthy Subjects. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3177-e3185.	3.6	4
3	Effect of Mild Physiologic Hyperglycemia on Insulin Secretion, Insulin Clearance, and Insulin Sensitivity in Healthy Glucose-Tolerant Subjects. Diabetes, 2021, 70, 204-213.	0.6	15
4	Pioglitazone corrects dysregulation of skeletal muscle mitochondrial proteins involved in ATP synthesis in type 2 diabetes. Metabolism: Clinical and Experimental, 2021, 114, 154416.	3.4	23
5	Impaired Suppression of Glucagon in Obese Subjects Parallels Decline in Insulin Sensitivity and Beta-Cell Function. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1398-1409.	3.6	16
6	Cardioprotective Effects of Pioglitazone in Type 2 Diabetes. Diabetes Spectrum, 2021, 34, 243-247.	1.0	1
7	The Insulin-Sensitizer Pioglitazone Remodels Adipose Tissue Phospholipids in Humans. Frontiers in Physiology, 2021, 12, 784391.	2.8	13
8	SUN-044 Gonadotropin Releasing Hormone (GnRH) Agonist Therapy Induces a Sustained Reduction in Plasma Testosterone Levels and Is Well Tolerated in Transwomen Veterans. Journal of the Endocrine Society, 2020, 4, .	0.2	0
9	Mechanism of Action of Inhaled Insulin on Whole Body Glucose Metabolism in Subjects with Type 2 Diabetes Mellitus. International Journal of Molecular Sciences, 2019, 20, 4230.	4.1	3
10	Mild Physiologic Hyperglycemia Induces Hepatic Insulin Resistance in Healthy Normal Glucose-Tolerant Participants. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2842-2850.	3.6	18
11	The potential role of the osteopontin"osteocalcin"osteoprotegerin triad in the pathogenesis of prediabetes in humans. Acta Diabetologica, 2018, 55, 139-148.	2.5	14
12	Effect of Chronic Hyperglycemia on Glucose Metabolism in Subjects With Normal Glucose Tolerance. Diabetes, 2018, 67, 2507-2517.	0.6	26
13	Adding fast-acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: <scp>A</scp> randomized, 18-week, open-label, phase 3 trial (onset 3). Diabetes, Obesity and Metabolism, 2017, 19, 1389-1396.	4.4	40
14	Islet amyloid polypeptide response to maximal hyperglycemia and arginine is altered in impaired glucose tolerance and type 2 diabetes mellitus. Acta Diabetologica, 2017, 54, 53-61.	2.5	7
15	Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes. Diabetes Care, 2016, 39, 2036-2041.	8.6	155
16	Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study. Hepatology, 2016, 64, 2028-2037.	7.3	78
17	Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOW. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2056-2062.	3.6	34
18	Effect of Dapagliflozin With and Without Acipimox on Insulin Sensitivity and Insulin Secretion in T2DM Males. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1249-1256.	3.6	30

#	ARTICLE	IF	CITATIONS
19	Transcriptomic Identification of ADH1B as a Novel Candidate Gene for Obesity and Insulin Resistance in Human Adipose Tissue in Mexican Americans from the Veterans Administration Genetic Epidemiology Study (VAGES). PLoS ONE, 2015, 10, e0119941.	2.5	35
20	Exenatide Regulates Cerebral Glucose Metabolism in Brain Areas Associated With Glucose Homeostasis and Reward System. Diabetes, 2015, 64, 3406-3412.	0.6	45
21	Dapagliflozin Lowers Plasma Glucose Concentration and Improves β -Cell Function. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1927-1932.	3.6	133
22	Sclerostin and Insulin Resistance in Prediabetes: Evidence of a Cross Talk Between Bone and Glucose Metabolism. Diabetes Care, 2015, 38, 1509-1517.	8.6	99
23	A Novel Insulin Resistance Index to Monitor Changes in Insulin Sensitivity and Glucose Tolerance: the ACT NOW Study. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1855-1862.	3.6	24
24	The Disposition Index Does Not Reflect β -Cell Function in IGT Subjects Treated With Pioglitazone. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3774-3781.	3.6	34
25	Strong Association Between Insulin-Mediated Glucose Uptake and the 2-Hour, Not the Fasting Plasma Glucose Concentration, in the Normal Glucose Tolerance Range. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3444-3449.	3.6	9
26	Baseline Adiponectin Levels Do Not Influence the Response to Pioglitazone in ACT NOW. Diabetes Care, 2014, 37, 1706-1711.	8.6	11
27	Chronic Reduction of Plasma Free Fatty Acid Improves Mitochondrial Function and Whole-Body Insulin Sensitivity in Obese and Type 2 Diabetic Individuals. Diabetes, 2014, 63, 2812-2820.	0.6	60
28	Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. Journal of Clinical Investigation, 2014, 124, 509-514.	8.2	661
29	Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3/TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study. Diabetologia, 2013, 56, 2153-2163.	6.3	71
30	Prevention of Diabetes With Pioglitazone in ACT NOW. Diabetes, 2013, 62, 3920-3926.	0.6	83
31	Prediction of Diabetes Based on Baseline Metabolic Characteristics in Individuals at High Risk. Diabetes Care, 2013, 36, 3607-3612.	8.6	55
32	Pioglitazone Slows Progression of Atherosclerosis in Prediabetes Independent of Changes in Cardiovascular Risk Factors. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 393-399.	2.4	97
33	The Effect of Nonsurgical Periodontal Therapy on Hemoglobin A _{1c} Levels in Persons With Type 2 Diabetes and Chronic Periodontitis. JAMA - Journal of the American Medical Association, 2013, 310, 2523.	7.4	211
34	Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance. New England Journal of Medicine, 2011, 364, 1104-1115.	27.0	646
35	Medical Therapy of Aortic Aneurysms: A Pathophysiology-Based Approach. Current Vascular Pharmacology, 2011, 9, 572-584.	1.7	4
36	Coordinated Defects in Hepatic Long Chain Fatty Acid Metabolism and Triglyceride Accumulation Contribute to Insulin Resistance in Non-Human Primates. PLoS ONE, 2011, 6, e27617.	2.5	33

#	ARTICLE	IF	CITATIONS
37	Defects in Insulin Secretion and Action in the Pathogenesis of Type 2 Diabetes Mellitus. <i>Current Diabetes Reports</i> , 2010, 10, 184-191.	4.2	83
38	Effect of Short-Term Free Fatty Acids Elevation on Mitochondrial Function in Skeletal Muscle of Healthy Individuals. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 422-429.	3.6	46
39	Proteomics Reveals Novel Oxidative and Glycolytic Mechanisms in Type 1 Diabetic Patients' Skin Which Are Normalized by Kidney-Pancreas Transplantation. <i>PLoS ONE</i> , 2010, 5, e9923.	2.5	60
40	Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes. <i>Diabetes Care</i> , 2009, 32, S157-S163.	8.6	1,423
41	Circulating Fibroblast Growth Factor-21 Is Elevated in Impaired Glucose Tolerance and Type 2 Diabetes and Correlates With Muscle and Hepatic Insulin Resistance. <i>Diabetes Care</i> , 2009, 32, 1542-1546.	8.6	341
42	The Crosstalk Between Insulin and Renin-Angiotensin-Aldosterone Signaling Systems and its Effect on Glucose Metabolism and Diabetes Prevention. <i>Current Vascular Pharmacology</i> , 2008, 6, 301-312.	1.7	76
43	Insulin Secretion and Action in Subjects With Impaired Fasting Glucose and Impaired Glucose Tolerance: Results From the Veterans Administration Genetic Epidemiology Study. <i>Diabetes</i> , 2006, 55, 1430-1435.	0.6	429
44	Contributions of β -Cell Dysfunction and Insulin Resistance to the Pathogenesis of Impaired Glucose Tolerance and Impaired Fasting Glucose. <i>Diabetes Care</i> , 2006, 29, 1130-1139.	8.6	382
45	Free Fatty Acid-Induced Insulin Resistance in the Obese Is Not Prevented by Rosiglitazone Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5058-5063.	3.6	20
46	Relationship Between Testosterone Levels, Insulin Sensitivity, and Mitochondrial Function in Men. <i>Diabetes Care</i> , 2005, 28, 1636-1642.	8.6	392
47	Anti-Inflammatory and Profibrinolytic Effect of Insulin in Acute ST-Segmentâ€Elevation Myocardial Infarction. <i>Circulation</i> , 2004, 109, 849-854.	1.6	280
48	Evidence for a Potent Antiinflammatory Effect of Rosiglitazone. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 2728-2735.	3.6	355
49	Contribution of Insulin-Stimulated Glucose Uptake and Basal Hepatic Insulin Sensitivity to Surrogate Measures of Insulin Sensitivity. <i>Diabetes Care</i> , 2004, 27, 2204-2210.	8.6	159
50	Differential effects of glucose and alcohol on reactive oxygen species generation and intranuclear nuclear factor- κ B in mononuclear cells. <i>Metabolism: Clinical and Experimental</i> , 2004, 53, 330-334.	3.4	139
51	Increase in intranuclear nuclear factor κ B and decrease in inhibitor κ B in mononuclear cells after a mixed meal: evidence for a proinflammatory effect. <i>American Journal of Clinical Nutrition</i> , 2004, 79, 682-690.	4.7	224
52	Free Fatty acids (FFA) and endothelial dysfunction; role of increased oxidative stress and inflammation. <i>Diabetologia</i> , 2003, 46, 300-301.	6.3	26
53	Elevation of Free Fatty Acids Induces Inflammation and Impairs Vascular Reactivity in Healthy Subjects. <i>Diabetes</i> , 2003, 52, 2882-2887.	0.6	546
54	Hypogonadotropic Hypogonadism in Erectile Dysfunction Associated with Type 2 Diabetes Mellitus: A Common Defect?. <i>Metabolic Syndrome and Related Disorders</i> , 2003, 1, 75-80.	1.3	26

#	ARTICLE	IF	CITATIONS
55	Importance of Obtaining Independent Measures of Insulin Secretion and Insulin Sensitivity During the Same Test. <i>Diabetes Care</i> , 2003, 26, 1395-1401.	8.6	67
56	Angiotensin II Receptor Blocker Valsartan Suppresses Reactive Oxygen Species Generation in Leukocytes, Nuclear Factor- κ B, in Mononuclear Cells of Normal Subjects: Evidence of an Antiinflammatory Action. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 4496-4501.	3.6	198
57	Control of Postprandial Plasma Glucose by an Oral Insulin Product (HIM2) in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2003, 26, 421-426.	8.6	91
58	Insulin Resistance as a Proinflammatory State: Mechanisms, Mediators, and Therapeutic Interventions. <i>Current Drug Targets</i> , 2003, 4, 487-492.	2.1	86
59	Hydrocortisone Suppresses Intranuclear Activator-Protein-1 (AP-1) Binding Activity in Mononuclear Cells and Plasma Matrix Metalloproteinase 2 and 9 (MMP-2 and MMP-9). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 5988-5988.	3.6	41
60	Serum Insulin and Lipid Profile in Normal Pregnant and Pregnancy-Induced Hypertensive Women from North India. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 1999, 39, 321-323.	1.0	2